Addendum
Addendum to Commission A13-09 (vandetanib)
Report documents
-
Addendum
Addendum to Commission A13-09 (vandetanib)
Press releases
Vandetanib: IQWiG assessed data subsequently submitted by the manufacturer
Hint of minor added benefit in people aged under 65 years / greater harm in people aged over 65 years
Additional information
Federal Joint Committee (G-BA)
2013-09-05 A G-BA decision was published.
Project details
- Project no.
- A13-26
- Commission
- Commission awarded on 24.07.2013 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decidess on the extent of the added benefit, thus completing the early benefit assessment
Connected Projects
-
Dossier assessment
Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed